Navigation Links
Genmab Reaches Milestones in Ofatumumab Collaboration
Date:1/21/2008

Summary: Genmab has Achieved Two Development Milestones in its Ofatumumab

Collaboration With GlaxoSmithKline.

COPENHAGEN, January 21 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it has reached the second and third development milestones for ofatumumab (HuMax-CD20(R)) under the terms of its collaboration with GlaxoSmithKline (GSK).

The second milestone payment of the collaboration of DKK 87.2 million was triggered by treatment of the first patient in the Phase II study of ofatumumab in Diffuse Large B-Cell Lymphoma (DLBCL), which occurred in 2007. The third milestone payment of DKK 87.2 million was triggered by the first patient receiving treatment in the Phase III rheumatoid arthritis (RA) program, which occurred in 2008.

Genmab achieved the first development milestone payment of DKK 116.3 million under the GSK collaboration in June, triggered by positive efficacy results in the Phase II RA study.

Ofatumumab is an investigational, fully human, next generation monoclonal antibody that targets a distinct small loop epitope on the CD20 receptor on the surface of B-cells. This epitope is different to the other anti-CD20 antibodies currently available or in development. Ofatumumab is being developed under a co-development and commercialization agreement between Genmab and GlaxoSmithKline.

"Genmab and GSK have worked hard to expand development with ofatumumab since our collaboration began in December 2006," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "The successful initiation of the ofatumumab RA and DLBCL programs are a testament to the cooperative spirit of our companies."

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for unmet medical needs. Using unique, cutting-edge antibody technology, Genmab's world class discovery and development teams have created and developed an ext
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Genmab Announces HuMax-CD32b Pre-Clinical Program
2. Roche Files IND for Second Genmab Antibody
3. Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma
4. Genmab Announces Details of Planned Ofatumumab Phase II Study in Multiple Sclerosis
5. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
6. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
7. Genmab Announces Results for the First Nine Months of 2007
8. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
9. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
10. Genmab A/S - Company Announcement
11. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... -- Theravalues Corporation annuncia con orgoglio il lancio di ... Hi Europe 2014 (dal 2 al 4 dicembre, ... curcumina con la maggiore biodisponibilità di sempre, con una ... dalle norme europee. La curcumina è un ... Curcuma longa ) che è stata associata con attività ...
(Date:11/24/2014)... BUENA, N.J. , Nov. 24, 2014  IGI ... Jersey based specialty generic pharmaceutical company, today ... application (ANDA) to the U.S. Food and Drug Administration ... submissions in 2014 to seven, with eighteen submissions now ... Grenfell-Gardner , President and CEO of the Company, commented, ...
(Date:11/24/2014)... , Nov. 24, 2014  Last week, Representatives ... Butterfield (D-NC) took a bold bipartisan step ... introducing the OPEN Act. Original co-sponsors of the ... The Act will incentivize drug makers and innovators ... diseases and pediatric cancers, which opens the door ...
(Date:11/24/2014)... 2014   First ... Elsevier , a world-leading provider of scientific, ... announce the launch of the latest title in the ... in Food Science . ... a new platform to keep up-to-date with the expanding volume ...
Breaking Biology Technology:La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3IGI Laboratories, Inc. Announces ANDA Submission 2OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 3
... Inclinix, Inc. has announced today that it has ... (Nasdaq: DATA ) to offer the most ... device companies globally. , ... DATATRAK,s eClinical(TM) platform to enhance its services as a ...
... Md., April 30 /PRNewswire/ -- ... company developing novel, proprietary antibodies for the treatment of ... will host a conference call and audio webcast on ... (3:00 pm Central European Time) to discuss its financial ...
... Inc. (NASDAQ: AEZS , TSX: AEZ), a ... will announce its first quarter 2009 financial and operating ... The Company will host a conference call and webcast ... 3:30 p.m., Eastern Time. , Participants may access the ...
Cached Biology Technology:DATATRAK International, Inc. Forms Strategic Partnership with Inclinix, Inc. 2DATATRAK International, Inc. Forms Strategic Partnership with Inclinix, Inc. 3DATATRAK International, Inc. Forms Strategic Partnership with Inclinix, Inc. 4Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009 2Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009 3Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009 4
(Date:11/4/2014)... , November 4, 2014   ... vertical market growth   Fuel3D , a ... closed a funding round totaling $6.4 million (£4 million). This ... funding secured earlier this year and paves the way for ... 2015. The funding round was led by Chimera ...
(Date:11/4/2014)... Lithuania , Nov. 4, 2014   ... technologies, today announced that the latest version of ... in the Ongoing MINEX evaluation organized ... of fingerprint algorithms using the INCITS 378 fingerprint ... mandatory requirement in public tenders in ...
(Date:11/3/2014)... Cancer Center study published in this month,s ... describes the activity of a recently discovered communication molecule ... It has been known to limit inflammation and the ... system: IL-37 inhibits the ability of the immune system ... mechanism that underlies IL-37,s effect on the immune system ...
Breaking Biology News(10 mins):Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3PNAS: From HIV to cancer, IL-37 regulates immune system 2
... Studies on genetically engineered mice show that social stress ... atherosclerosis. Commonly used drugs to reduce blood pressure, however, ... a thesis presented at the University of Gothenburg, Sweden. ... is a correlation between psychosocial stress and the risk ...
... heart defects has been identified by a team of scientists, ... to new treatments for those affected by the conditions brought ... on identifying and studying the gene in zebrafish embryos, and ... studying the genetics of mice and people. "This ...
... 6, 2010 Parascript, LLC, the image analysis ... its Signature Xpert was awarded best performance ... Conference on Frontiers in Handwriting Recognition (ICFHR2010) in ... Parascript was among seven participants representing a total ...
Cached Biology News:Social stress leads to atherosclerosis 2Scientists find gene linked to congenital heart defect 2Scientists find gene linked to congenital heart defect 3Scientists find gene linked to congenital heart defect 4Parascript SignatureXpert Wins Forensic Signature Verification Competition 2
Designed for flow cytometric applications intended to identify...
MOUSE ANTI RAT RT1Bu / MOUSE Ia:BIOTIN Immunogen: Rat thymocyte membrane glycoproteins...
MOUSE ANTI GUINEA PIG T-CELLS (PAN):FITC Immunogen: Guinea pig peritoneal T-cells...
MOUSE ANTI RABBIT T LYMPHOCTYES Immunogen: Rabbit Thymocytes...
Biology Products: